TCF4 and melanoma: Genetic targeting of TCF4 or using bromodomain and extra-terminal motif (BET) inhibitors has been shown to enhance melanoma cell recognition by T cells in co-culture experiments, increasing the sensitivity of melanoma lesions to ICB in mouse models (62–64).